Xinhuanet, Nanjing, May 23 (Reporter: Zhu Cheng) - On May 22, local time, the American Society of Clinical Oncology (ASCO) annual meeting announced the abstracts for selected studies. Among them, data from the Phase III clinical trial of the "Defu Combination" (Benmelstobart + Anlotinib capsules) from leading Hong Kong-listed pharmaceutical company Sino Biopharm for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC) was announced.

Professor Shi Yuankai from the Cancer Hospital of the Chinese Academy of Medical Sciences stated that the regimen of Benmelstobart combined with chemotherapy followed by sequential combination with Anlotinib has broken through the bottleneck of traditional standard treatments and may change the existing treatment paradigm, providing an innovative first-line treatment model for patients with advanced squamous non-small cell lung cancer who have limited clinical treatment options.

On May 16, there was more good news for Meloxicam Injection (II), a non-opioid analgesic new drug for which Sino Biopharm (1177.HK) holds exclusive commercialization rights in Chinese mainland. Recently, the New Drug Application (NDA) for this product was formally approved by both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA). In China, it was approved as a Class 2.2 new chemical drug for the management of post-operative pain in adults, becoming China's first once-daily, 24-hour long-acting non-steroidal anti-inflammatory drug (NSAID) injection. It is also the first analgesic new drug from China to receive FDA approval and the world's only commercially available long-acting NSAID injection.

On April 22, the Sino Biopharm Leading (Shanghai) Private Investment Fund (hereinafter referred to as the "Sino Biopharm Leading Fund") was unveiled and established in the Pudong New Area. This is a major initiative by Sino Biopharm to invest in, empower, and cultivate innovation, following its commitment to comprehensive innovation and the achievement of leapfrog innovative development.

On March 20, Sino Biopharm (HK.01177) released its 2024 annual results report, delivering an impressive "double-digit growth" across two key metrics: full-year revenue for 2024 reached RMB 28.87 billion, a year-on-year increase of 10.2%, hitting a record high; adjusted net profit attributable to owners of the parent company reached RMB 3.46 billion, a year-on-year increase of 33.5%.

Recently, the 2025 "Forbes China's Top 100 Outstanding Businesswomen" list was officially released. Miss Theresa Tse, Chairwoman of the Board of Sino Biopharm (1177.HK), was named to the list, marking the seventh time she has been honored with this award.